A copy post from IHUB by falconer66a...... ,
Fletch
Anavex Life Sciences (AVXL)
3.062 ▲ 0.162 (5.59%)
Volume: 98,674 @09/11/19 10:51:53 AM EDT
Bid Ask Day's Range
3.03 3.07 2.91 - 3.07
AVXL Detailed Quote
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/16/2019 6:01:11 AM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 7/3/2019 4:33:43 PM
Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in P... GlobeNewswire Inc. - 6/25/2019 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2019 5:02:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 4:59:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 7:28:42 PM
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndro... GlobeNewswire Inc. - 6/6/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 6:12:48 AM
Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in P... GlobeNewswire Inc. - 5/8/2019 8:00:00 AM
Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2019 4:33:58 PM
Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019 GlobeNewswire Inc. - 5/6/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/8/2019 4:40:20 PM
Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire Inc. - 4/5/2019 4:01:00 PM
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurothe... GlobeNewswire Inc. - 3/28/2019 7:00:00 AM
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development Business Wire - 3/20/2019 9:00:00 AM
falconer66a Wednesday, 09/11/19 09:51:01 AM
Re: basparks79 post# 209181 0
Post # of 209232
Most Important Statement: Confirms Anavex 2-73 Efficacy
Quote:
... a nice reporting of Alz patients continuing to do well, after 3 years, on higher dosage of 2-73.
I was not able to connect to hear Missling’s statements, and haven’t found a recording or posting of them yet. But if the good doctor (PhD) made this statement, he formally announced that Anavex is following the Australians with Alzheimer’s who are now in their third year of Anavex 2-73 therapy. The stuff works.
Does this beat the Alzheimer’s Standard of Care (SOC) drug, Aricept (donepezil), the only drug presently available to treat the disease? Sure, donepezil works, moderately, for a time. It will “...provide a temporary reprieve from dementia linked to Alzheimer’s....” It merely slows the progression of the disease. In every case, the debilitating dementia lethally resumes. (Know this personally, as my father died of Alzheimer’s; participated in the drug trial that caused the FDA to approve donepezil’s sale and use.)
If your dad had Alzheimer’s, which drug would you prefer he took. Aricept, a “proven,” well-used therapeutic? Or, Anavex 2-73, which for a good number of Alzheimer’s patients in Australia has stopped the progression of their dementias for neigh on to three years now?
What thoughts go through the minds of health care administrators in Australia, burdened with the caring for of ever greater thousands of elderly people being diagnosed with Alzheimer’s? Aricept? Or Anavex 2-73?
If what Dr. Missling said is so, that Alzheimer’s patients taking sufficient doses of Anavex 2-73 have had the progression of their dementias suppressed for three years, what, then, would be the implication of administering the drug at the very first indications of Alzheimer’s onset? As several have reported, there are a number of new clinical tests and observations that appear to reveal the disease before dementia, itself, is exhibited.
Supports my previous contention that perhaps the greatest therapeutic use of Anavex 2-73 will be as a prophylactic; a drug that prevents both the onset and progression of a disease.)
Sometime soon In a physician’s office? “Mr. Dorglemyer, I’ve just reviewed the numbers from your checkup we did last week. They show that you are coming down with Alzheimer’s. But fortunately, there is this new drug, blarcamesine [Anavex 2-73], which I’ll prescribe for you. Your insurance will pay for it. It’ll keep your mind clear on out. Just be sure to take the tablet every morning. So glad we found your Alzheimer’s so soon, and now, thankfully, have a drug that will allow you to live normally for the rest of your life.”
Perhaps the first Mr. Dorglemyer will be some fellow in Australia; where Anavex 2-73 first gets regulatory approval for therapeutic use.
https://investorshub.advfn.com/boards/read_ms...=151060069
Fletch
Anavex Life Sciences (AVXL)
3.062 ▲ 0.162 (5.59%)
Volume: 98,674 @09/11/19 10:51:53 AM EDT
Bid Ask Day's Range
3.03 3.07 2.91 - 3.07
AVXL Detailed Quote
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/16/2019 6:01:11 AM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 7/3/2019 4:33:43 PM
Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in P... GlobeNewswire Inc. - 6/25/2019 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2019 5:02:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 4:59:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 7:28:42 PM
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndro... GlobeNewswire Inc. - 6/6/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 6:12:48 AM
Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in P... GlobeNewswire Inc. - 5/8/2019 8:00:00 AM
Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2019 4:33:58 PM
Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019 GlobeNewswire Inc. - 5/6/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/8/2019 4:40:20 PM
Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire Inc. - 4/5/2019 4:01:00 PM
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurothe... GlobeNewswire Inc. - 3/28/2019 7:00:00 AM
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development Business Wire - 3/20/2019 9:00:00 AM
falconer66a Wednesday, 09/11/19 09:51:01 AM
Re: basparks79 post# 209181 0
Post # of 209232
Most Important Statement: Confirms Anavex 2-73 Efficacy
Quote:
... a nice reporting of Alz patients continuing to do well, after 3 years, on higher dosage of 2-73.
I was not able to connect to hear Missling’s statements, and haven’t found a recording or posting of them yet. But if the good doctor (PhD) made this statement, he formally announced that Anavex is following the Australians with Alzheimer’s who are now in their third year of Anavex 2-73 therapy. The stuff works.
Does this beat the Alzheimer’s Standard of Care (SOC) drug, Aricept (donepezil), the only drug presently available to treat the disease? Sure, donepezil works, moderately, for a time. It will “...provide a temporary reprieve from dementia linked to Alzheimer’s....” It merely slows the progression of the disease. In every case, the debilitating dementia lethally resumes. (Know this personally, as my father died of Alzheimer’s; participated in the drug trial that caused the FDA to approve donepezil’s sale and use.)
If your dad had Alzheimer’s, which drug would you prefer he took. Aricept, a “proven,” well-used therapeutic? Or, Anavex 2-73, which for a good number of Alzheimer’s patients in Australia has stopped the progression of their dementias for neigh on to three years now?
What thoughts go through the minds of health care administrators in Australia, burdened with the caring for of ever greater thousands of elderly people being diagnosed with Alzheimer’s? Aricept? Or Anavex 2-73?
If what Dr. Missling said is so, that Alzheimer’s patients taking sufficient doses of Anavex 2-73 have had the progression of their dementias suppressed for three years, what, then, would be the implication of administering the drug at the very first indications of Alzheimer’s onset? As several have reported, there are a number of new clinical tests and observations that appear to reveal the disease before dementia, itself, is exhibited.
Supports my previous contention that perhaps the greatest therapeutic use of Anavex 2-73 will be as a prophylactic; a drug that prevents both the onset and progression of a disease.)
Sometime soon In a physician’s office? “Mr. Dorglemyer, I’ve just reviewed the numbers from your checkup we did last week. They show that you are coming down with Alzheimer’s. But fortunately, there is this new drug, blarcamesine [Anavex 2-73], which I’ll prescribe for you. Your insurance will pay for it. It’ll keep your mind clear on out. Just be sure to take the tablet every morning. So glad we found your Alzheimer’s so soon, and now, thankfully, have a drug that will allow you to live normally for the rest of your life.”
Perhaps the first Mr. Dorglemyer will be some fellow in Australia; where Anavex 2-73 first gets regulatory approval for therapeutic use.
https://investorshub.advfn.com/boards/read_ms...=151060069
